Indivior PLC (INDV) Beats Q3 Earnings and Revenue Estimates

Core Insights - Indivior PLC reported quarterly earnings of $0.72 per share, exceeding the Zacks Consensus Estimate of $0.38 per share, and showing an increase from $0.54 per share a year ago, resulting in an earnings surprise of +89.47% [1][2] - The company achieved revenues of $314 million for the quarter ended September 2025, surpassing the Zacks Consensus Estimate by 20.81%, and showing a slight increase from $307 million year-over-year [2] - Indivior shares have increased by approximately 103.1% since the beginning of the year, significantly outperforming the S&P 500's gain of 17.2% [3] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is $0.40 on revenues of $255.13 million, and for the current fiscal year, it is $1.72 on revenues of $1.08 billion [7] - The estimate revisions trend for Indivior was mixed prior to the earnings release, resulting in a Zacks Rank 3 (Hold) for the stock, indicating expected performance in line with the market [6] Industry Context - The Medical - Drugs industry, to which Indivior belongs, is currently ranked in the top 37% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8]